Meningococcal disease is a serious bacterial infection that can result in organ damage or death. The disease is treated with antibiotics. Early meningococcal disease treatment is important, and vaccination is a step towards prevention. According to the World Health Organization (WHO), antibiotics, when given promptly, decreases the risk of transmission. Antibiotics help prevent infection in people at high risk of meningococcal disease.Controlling epidemics of the disease depends on both antibiotics and vaccination.
Both antibiotics and vaccination is the most effective way to reduce the impact and burden of meningococcal disease by delivering long-lasting protection. Meningococcal disease is caused by bacteria, called Neisseria meningitidis. There are many signs and symptoms of the disease. People should contact a healthcare provider immediately if they have any of these symptoms. Thus, it is very important to get an early diagnosis. Complete recovery may take some time. This is especially true if you have complications.
As per report published by Coherent Market Insights, Meningococcal Disease Treatment Market is estimated to be valued at US$ 3,754.1 million in 2021 and is expected to exhibit a CAGR of 12.6% over the forecast period (2021-2028).
The disease is a serious bacterial infection, which may lead to high rates of death and disability. In the United States, serogroups B, C, and Y cause most meningococcal infections. According to the Centers for Disease Control and Prevention (CDC), in 2019, there were about 375 total cases of meningococcal disease reported in the United States. However, rates of meningococcal disease have declined in the U.S. since the 1990s and remain low. But still there has been an increase in the demand for safe/effective meningococcal disease treatment.
Meningococcal diseasecan affect people of all ages, but it can be prevented with vaccination. The Food and Drug Administration (FDA) approved Trumenba (in 2018) to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age. Keeping up to date with recommended vaccines is the best protection against meningococcal disease. Furthermore, the meningococcal shots (vaccines) are safe and effective at preventing meningococcal disease.
